Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations

PURPOSE: Somatic mutations and copy number variation in the ERBB family are frequent in urothelial carcinoma (UC) and may represent viable therapeutic targets. We studied whether afatinib (an oral, irreversible inhibitor of the ErbB family) has activity in UC and if specific ERBB molecular alteratio...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Choudhury, Noura J., Campanile, Alexa, Antic, Tatjana, Yap, Kai Lee, Fitzpatrick, Carrie A., Wade, James L., Karrison, Theodore, Stadler, Walter M., Nakamura, Yusuke, O’Donnell, Peter H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2016
Gaiak:
ORIGINAL REPORTS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569685/
https://ncbi.nlm.nih.gov/pubmed/27044931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.66.3047
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak